24Apr 2022
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

Entrectinib is a kinase inhibitor that targets both the NTRK and ROS1 oncogenes. This study shows that NTRK and ROS1 fusions are present in 46% and 64% of blood samples from patients enrolled on a clinical trial, with a response rate of 72%. Genomic tumour profiling informs targeted treatment options. This study evaluated the clinical validity of F1L CDx as an aid in identifying patients with NTRK‐fp or ROS1‐fp tumours and assessed the genomic landscape pre-and post‐entrectinib treatment. It was concluded that F1L CDx is a clinically useful complement to tissue‐based testing to identify patients who may benefit from entrectinib and those with acquired resistance mutations associated with disease progression.

  • #oncology

Like

Save

Share